Ethosuximide (Epilepsy)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S6495
R17810		 Bànhidy (Ethosuximide), 2011 Hypospadias throughout pregnancy case control unexposed, sick Adjustment: No Matched 3.80 [0.06;243.53] C 0/   3/13 3 0
ref
S6065
R15777		 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 4.28 [0.23;80.64] C 0/12   6/647 6 12
ref
Total 2 studies 4.12 [0.37;45.30] 9 12
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Ethosuximide), 2011Bànhidy, 2011 1 3.80[0.06; 243.53]3-33%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 4.28[0.23; 80.64]61267%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 4.12[0.37; 45.30]9120.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Ethosuximide; 2: Ethosuximide) (Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 4.28[0.23; 80.64]612 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 case control studiescase control studies 3.80[0.06; 243.53]3- -NABànhidy (Ethosuximide), 2011 1 Type of controls unexposed, sickunexposed, sick 3.80[0.06; 243.53]3- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sickexposed to other treatment, sick 4.28[0.23; 80.64]612 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 4.12[0.37; 45.30]9120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 2 MatchedMatched 3.80[0.06; 243.53]3- -NABànhidy (Ethosuximide), 2011 1 All studiesAll studies 4.12[0.37; 45.30]9120%NABànhidy (Ethosuximide), 2011 Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.80[0.06; 243.53]3- -NABànhidy (Ethosuximide), 2011 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 4.28[0.23; 80.64]612 -NAMorrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 10.510.01.0